ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. Eric Weisblum, CEO of Silo Pharma commented “The successful results of our study show that the…
